This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Joo-Hyun Nam, Asan Medical Center
Boryung Pharmaceutical Co., Ltd
Information provided by (Responsible Party):
Joo-Hyun Nam, Asan Medical Center Identifier:
First received: October 25, 2011
Last updated: May 27, 2017
Last verified: May 2017
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.

Condition Intervention Phase
Advanced or Recurrent Endometrial Cancer Drug: Doctaxel Drug: Cisplatin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer

Resource links provided by NLM:

Further study details as provided by Joo-Hyun Nam, Asan Medical Center:

Primary Outcome Measures:
  • Response rate [ Time Frame: 3 months after completion of study treatment ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 2 years after completion of study treatment ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Before each chemotherapy, an expected average of 3 weeks ]
  • Quality of life [ Time Frame: 3 months after completion of study treatment ]

Estimated Enrollment: 59
Study Start Date: October 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Chemotherapy
Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
Drug: Doctaxel
Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
Drug: Cisplatin
Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed chemotherapy naïve endometrial cancer
  • One of following histology Endometrioid, UPSC, CCCa, squamous, adenosquamous, mixed
  • FIGO stage IVb or recurrent endometrial cancer (incurable by surgery and/or RT)
  • At least one measurable lesion by RECIST on CT
  • ECOG PS: 0-2
  • Age: 20-75
  • Adequate organ function BM: ANC≥1,000/mm3, Plt≥100X103/mm3 Kidney: Creatinine<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT< 3×UNL, T- bil<1.5 mg/ mm3
  • Informed Consent
  • Contraception during study period

Exclusion Criteria:

  • Previous chemotherapy
  • RT, hormone therapy, or immunotherapy within 1 month
  • Other malignant disease
  • Uncontrolled medical disease
  • Infection requiring antibiotics
  • Symptomatic CHF, RF, Angina, Arrhythmia, etc.
  • Neurosis or psychosis
  • Pregnancy, breast-feeding
  • Etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01461759

Contact: Joo-Hyun Nam, M.D., Ph.D. +82-2-3010-3633
Contact: Jeong-Yeol Park, M.D., Ph.D. +82-2-3010-3646

Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Joo-Hyun Nam, M.D., Ph.D    +82-2-3010-3633   
Sponsors and Collaborators
Asan Medical Center
Boryung Pharmaceutical Co., Ltd
  More Information

Responsible Party: Joo-Hyun Nam, Professor, Asan Medical Center Identifier: NCT01461759     History of Changes
Other Study ID Numbers: ANSGOG-002
Study First Received: October 25, 2011
Last Updated: May 27, 2017

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017